Tacabrutideg is a next-generation, orally bioavailable small-molecule BTK-targeting proteolysis-targeting chimera (PROTAC) developed by BeOne Medicines.
Orforglipron (Foundayo™ (US)) is a next-generation, orally available, non-peptide small-molecule GLP-1 receptor agonist (discovered by Chugai and developed/commercialized by Eli Lilly).
Sonrotoclax is a next-generation, highly selective, oral B-cell lymphoma-2 (BCL-2) inhibitor originally developed by BeiGene.
Etripamil is a first-in-class, short-acting intranasal L-type calcium-channel blocker originally developed by Milestone Pharmaceuticals.
Aficamten (brand name Myqorzo) is a next-in-class, oral cardiac myosin inhibitor originally discovered and developed by Cytokinetics.
Pimicotinib is an oral small-molecule, highly selective CSF-1R inhibitor developed by Abbisko Therapeutics.